SPRAVATO 28mg 2s (Esketamine Hydrochloride Nasal Spray) 28mg/0.2ml

Spravato 28mg nasal spray offers rapid-acting support for treatment-resistant depression and acute suicidal ideation. This esketamine-based therapy is designed for supervised use in clinical settings. Store below 25°C to maintain potency. Ideal for patients seeking adjunctive options in mental health management.

Strength

28mg/0.2ml

Pack Size

Storage

Below 25°C

Manufacturer / TM Owner

Janssen Pharmaceuticals Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Spravato 28mg nasal spray is used as an adjunctive treatment for adults with treatment-resistant depression who have not responded to conventional antidepressants. It is also indicated for the rapid reduction of depressive symptoms in adults with major depressive disorder experiencing acute suicidal thoughts or behaviors. This therapy is typically administered in a certified healthcare setting under professional supervision.

Side Effects

Users may experience a temporary sense of dissociation or altered perception shortly after administration, which typically resolves within hours. Some individuals report improved mood or reduced depressive symptoms over time with consistent use. Effects vary by individual and are closely monitored during and after treatment sessions.

Precautions & Warnings

Spravato should only be used under direct medical supervision in a certified healthcare setting. Patients must remain under observation for at least 2 hours post-dose due to potential side effects. Avoid operating machinery or driving until fully recovered. Keep out of reach of children and pets.

Avoid Interactions

Avoid alcohol and central nervous system depressants during treatment, as they may increase sedation. Inform your healthcare provider about all medications, including over-the-counter drugs and supplements. Caution is advised when combining with other psychotropic medications, as interactions may occur.

Frequently Asked Questions

Spravato is used as an adjunctive treatment for treatment-resistant depression and for rapid reduction of depressive symptoms in adults with acute suicidal ideation.

Spravato is administered as a nasal spray in a certified healthcare setting, with doses spaced at least 1 week apart.

Common side effects may include dissociation, dizziness, nausea, and increased blood pressure.

No, Spravato must be administered in a healthcare setting under professional supervision.

Store Spravato below 25°C and protect from light. Keep out of reach of children.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.